We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed at $65 in the latest trading session, marking a -0.28% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.13%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq gained 0.16%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 1.27% in the past month. In that same time, the Medical sector lost 5.51%, while the S&P 500 lost 7.59%.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.53 per share. This would mark a year-over-year decline of 42.26%. Our most recent consensus estimate is calling for quarterly revenue of $6.09 billion, down 17.96% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.63 per share and revenue of $25.26 billion. These totals would mark changes of -8.93% and -7.47%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 9.83 right now. This represents a discount compared to its industry's average Forward P/E of 20.28.
It is also worth noting that GILD currently has a PEG ratio of 0.67. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Stock Moves -0.28%: What You Should Know
Gilead Sciences (GILD - Free Report) closed at $65 in the latest trading session, marking a -0.28% move from the prior day. This change was narrower than the S&P 500's daily loss of 1.13%. At the same time, the Dow lost 0.56%, and the tech-heavy Nasdaq gained 0.16%.
Coming into today, shares of the HIV and hepatitis C drugmaker had lost 1.27% in the past month. In that same time, the Medical sector lost 5.51%, while the S&P 500 lost 7.59%.
Investors will be hoping for strength from Gilead Sciences as it approaches its next earnings release. In that report, analysts expect Gilead Sciences to post earnings of $1.53 per share. This would mark a year-over-year decline of 42.26%. Our most recent consensus estimate is calling for quarterly revenue of $6.09 billion, down 17.96% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.63 per share and revenue of $25.26 billion. These totals would mark changes of -8.93% and -7.47%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.05% higher. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 9.83 right now. This represents a discount compared to its industry's average Forward P/E of 20.28.
It is also worth noting that GILD currently has a PEG ratio of 0.67. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.36 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.